Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sjogren's syndrome is associated with and not secondary to systemic sclerosis.
Salliot C, Mouthon L, Ardizzone M, Sibilia J, Guillevin L, Gottenberg JE, Mariette X. Salliot C, et al. Among authors: ardizzone m. Rheumatology (Oxford). 2007 Feb;46(2):321-6. doi: 10.1093/rheumatology/kel252. Epub 2006 Jul 28. Rheumatology (Oxford). 2007. PMID: 16877466 Review.
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.
Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Gottenberg JE, et al. Among authors: ardizzone m. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5. doi: 10.1073/pnas.0510837103. Epub 2006 Feb 13. Proc Natl Acad Sci U S A. 2006. PMID: 16477017 Free PMC article.
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.
Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P. Gottenberg JE, et al. Among authors: ardizzone m. JAMA. 2016 Sep 20;316(11):1172-1180. doi: 10.1001/jama.2016.13512. JAMA. 2016. PMID: 27654603
Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients.
Danion F, Sparsa L, Arnaud L, Alsaleh G, Lefebvre F, Gies V, Martin T, Lukas C, Durckel J, Ardizzone M, Javier RM, Kleinmann JF, Moreau P, Blaison G, Goetz J, Chatelus E, Gottenberg JE, Sibilia J, Sordet C. Danion F, et al. Among authors: ardizzone m. RMD Open. 2017 Dec 29;3(2):e000555. doi: 10.1136/rmdopen-2017-000555. eCollection 2017. RMD Open. 2017. PMID: 29435362 Free PMC article.
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study.
Schlencker A, Messer L, Ardizzone M, Blaison G, Hinschberger O, Dahan E, Sordet C, Walther J, Dory A, Gonzalez M, Kleinlogel S, Bramont-Nachman A, Barrand L, Payen-Revol I, Sibilia J, Martin T, Arnaud L. Schlencker A, et al. Among authors: ardizzone m. Lupus Sci Med. 2022 May;9(1):e000700. doi: 10.1136/lupus-2022-000700. Lupus Sci Med. 2022. PMID: 35568439 Free PMC article.
Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017.
Richebé P, Coiffier G, Guggenbuhl P, Mulleman D, Couderc M, Dernis E, Deprez V, Salliot C, Urien S, Brault R, Ruyssen-Witrand A, Hoppe E, Chatelus E, Roux CH, Ottaviani S, Baufrere M, Michaut A, Pauvele L, Darrieutort-Laffite C, Wendling D, Coquerelle P, Bart G, Gervais E, Goeb V, Ardizzone M, Pertuiset E, Derolez S, Ziza JM, Flipo RM, Godot S, Seror R. Richebé P, et al. Among authors: ardizzone m. Ann Rheum Dis. 2022 Jul 12:annrheumdis-2022-222143. doi: 10.1136/ard-2022-222143. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35820674
B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics.
Felten R, Duret PM, Bauer E, Sedmak N, Djossou JH, Bensalem M, Ardizzone M, Geoffroy M, Fan A, Couderc M, Salmon JH, Messer L, Javier RM, Meyer A, Chatelus E, Sordet C, Pijnenburg L, Fort J, Rinagel M, Walther J, Fabre C, Arnaud L, Sibilia J, Meyer N, Berenbaum F, Chary-Valckenaere I, Soubrier M, Sellam J, Gottenberg JE. Felten R, et al. Among authors: ardizzone m. Ann Rheum Dis. 2022 Jan;81(1):143-145. doi: 10.1136/annrheumdis-2021-220549. Epub 2021 Sep 23. Ann Rheum Dis. 2022. PMID: 34556483 No abstract available.
Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides.
Felten R, Geoffroy M, Bolko L, Duret PM, Desmurs M, Fan A, Couderc M, Laurent M, Ardizzone M, Ahmed-Yahia S, Javier RM, Meyer A, Chatelus E, Sordet C, Pijnenburg L, Sibilia J, Soubrier M, Gottenberg JE, Salmon JH. Felten R, et al. Among authors: ardizzone m. Joint Bone Spine. 2022 Oct;89(5):105391. doi: 10.1016/j.jbspin.2022.105391. Epub 2022 Apr 28. Joint Bone Spine. 2022. PMID: 35490948 Free PMC article. No abstract available.
101 results